![](https://news.europawire.eu/wp-content/uploads/2023/09/novartis-pavillon-scaled-e1733739094175-144x144.jpg)
(IN BRIEF) Novartis has presented compelling data from the SMART study, reinforcing the clinical advantages of Zolgensma® (onasemnogene abeparvovec) in treating spinal muscular atrophy (SMA) patients weighing ≥ 8.5 kg to ≤ 21 kg, with a mean age of 4.69 … Read the full press release